Sutton G P, Blessing J A, Homesley H D, Malfetano J H
Section of Gynecologic Oncology, Indiana University Medical School, Indianapolis 46202.
Gynecol Oncol. 1994 Apr;53(1):24-6. doi: 10.1006/gyno.1994.1081.
A phase II trial of ifosfamide and mesna in women with mixed mesodermal tumors of the ovary who had previously received platinum-containing chemotherapy was conducted by the Gynecologic Oncology Group (GOG). The starting dose of ifosfamide was 1.2 g/m2 daily iv for 5 days. Mesna was given intravenously with and at 4 and 8 hr following the administration of ifosfamide. Each dose of mesna was 20% of the total daily dose of ifosfamide. Thirty-two patients were placed on the study; 31 were evaluable for toxicity and 28 for response. Twenty-seven patients (87.1%) had previously undergone surgery and three (9.3%) had received radiotherapy before this trial. GOG grade 3 or 4 granulocytopenia occurred in 11 (35.5%) patients, and one (3.2%) developed grade 4 thrombocytopenia. Two patients (6.4%) had grade 3 neurotoxicity. A complete response was observed in one patient (3.6%) and partial responses in four patients (14.3%) for a total response rate of 17.9% (95% confidence interval = 6.1-36.9%). In conclusion, ifosfamide has activity in previously mixed mesodermal tumors of the ovary.
妇科肿瘤学组（GOG）开展了一项关于异环磷酰胺和美司钠的II期试验，受试对象为先前接受过含铂化疗的卵巢混合性中胚层肿瘤女性患者。异环磷酰胺的起始剂量为每日1.2 g/m²，静脉注射，共5天。美司钠在异环磷酰胺给药时、给药后4小时和8小时静脉注射。美司钠的每次剂量为异环磷酰胺每日总剂量的20%。32例患者参与了该研究；31例可评估毒性，28例可评估疗效。27例患者（87.1%）此前接受过手术，3例（9.3%）在本次试验前接受过放疗。11例患者（35.5%）出现了GOG 3级或4级粒细胞减少，1例（3.2%）出现了4级血小板减少。2例患者（6.4%）出现了3级神经毒性。1例患者（3.6%）出现完全缓解，4例患者（14.3%）出现部分缓解，总缓解率为17.9%（95%置信区间=6.1 - 36.9%）。总之，异环磷酰胺对先前的卵巢混合性中胚层肿瘤具有活性。
